How Proactive Regulatory Planning Supports Improved Drug Formulation And Manufacture

By Rajendra Nagamalla, CorePharma

Establishing a proactive regulatory strategy during early drug development is essential to align R&D with manufacturing and avoiding costly delays. This integrated approach ensures formulation decisions support the intended regulatory pathway while accounting for evolving guidance and limited internal resources. Because technical and regulatory functions are deeply interconnected, siloing these departments often leads to significant downstream risks.

Partnering with experienced third-party experts, such as CDMOs or specialized consultants, provides the practical insight needed to demystify technical requirements and mitigate risk. By continuously reassessing critical quality attributes and maintaining close coordination with regulators, sponsors can navigate complex hurdles—like impurity limits or batch requirements—to achieve more efficient, predictable development outcomes.